The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Open accessAbstract
The Journal of Cancer Metastasis and Treatment is an open access journal focused on cancer metastasis and treatment, including the occurrence, development, progression, metastasis, and treatment of oncologic disease. It covers basic, translational and clinical research related to cancer cell biology, genomics, precision medicine, oncology internal medicine, radiotherapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neurooncology, etc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“The intrinsic immunological ability of an individual to combat cancer has been called the “cancer– immune set point”, and is influenced by a complex set of factors involving the tumor, the host, and environmental factors[41].”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“PD-1 was cloned in 1992[63], and its ligands PD-L1 and PDL2, which are members of the B7 ligand family, were later characterized[64-66].”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Since the CTLA-4/B7 synapse acts earlier than the PD1/PDL-1 synapse in the immune response, CTLA4 is considered the “leader” of the immune checkpoint inhibitors, because it stops potentially autoreactive T-cells at the initial or priming stage of naive T-cell activation, occurring chiefly within lymph nodes[62,69].”
BackgroundSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“In a recent meta-analysis of ipilimumab, a monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), a type of immune checkpoint receptor or negative regulator of T-cell immune function, more than 20% of patients with metastatic melanoma who received a single round of treatment were alive…”
BackgroundImmune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
ZINKERNAGEL, R. M., & DOHERTY, P. C. (1974) · Nature · doi:10.1038/248701a0 · Cited by 2,095
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Lindahl, T., & Wood, R. D. (1999) · Science · doi:10.1126/science.286.5446.1897 · Cited by 1,494
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
COLEY, W. B. (1991) · PubMed · Cited by 965
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Herberman, R. B., Nunn, M. E., Holden, H. T., & Lavrin, D. H. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910160205 · Cited by 885
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
ZINKERNAGEL, R. M., & DOHERTY, P. C. (1974) · Nature · doi:10.1038/251547a0 · Cited by 853
Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia
Quesada, J. R., Reuben, J., Manning, J. T., Hersh, E. M., & Gutterman, J. U. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401053100104 · Cited by 820
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.2.380 · Cited by 814
Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Plückthun, A., Elliott, T., Hengartner, H., & Zinkernagel, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1383 · Cited by 763
Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions.
Hozumi, N., & Tonegawa, S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3628 · Cited by 759
Brodin, P., & Davis, M. M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2016.125 · Cited by 730
Quantitative Studies on Tissue Transplantation Immunity. III. Actively Acquired Tolerance
Billingham, R. E., Brent, L., & Medawar, P. B. (1956) · Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences · doi:10.1098/rstb.1956.0006 · Cited by 684
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Burstein, H. J., Krilov, L., Aragon-Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., De Groot, J. F., Devine, S. M., DuBois, S. G., El-Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 601
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Cellular and Humoral Aspects of the Hypersensitive States
(1959) · Pediatrics · doi:10.1542/peds.24.5.773 · Cited by 581
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
Allison, J. P., McIntyre, B. W., & Bloch, D. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2293 · Cited by 541
Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse
OLD, L. J., CLARKE, D. A., & BENACERRAF, B. (1959) · Nature · doi:10.1038/184291a0 · Cited by 539
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5023.841 · Cited by 505
on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Kroschinsky, F., Stölzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., & Schellongowski, P. (2017) · Critical Care · doi:10.1186/s13054-017-1678-1 · Cited by 500
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
Defective LPS signaling in C3 H/HeJ and C57 BL/10 ScCr mice: Mutations in Tlr4 Gene
Poltorak, A. N., xiao-kui, H., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Suvá, M., Galanos, C., et al. (1999) · Pneumologie · Cited by 426
Human cancers express mutator phenotypes: origin, consequences and targeting
Loeb, L. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3063 · Cited by 396
The onset and extent of genomic instability in sporadic colorectal tumor progression
Stoler, D. L., Chen, N., Basik, M., Kahlenberg, M. S., Rodriguez-Bigas, M. A., Petrelli, N. J., & Anderson, G. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15121 · Cited by 383
The Spontaneous Regression of Cancer: A review of cases from 1900 to 1987
Challis, G. B., & Stam, H. J. (1990) · Acta Oncologica · doi:10.3109/02841869009090048 · Cited by 372
CRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351 · cited 1×
“Some may be expressed by the cell in a free soluble form, such as indoleamine 2,3-dioxygenase (IDO1), an enzyme produced by some activated macrophages and also overexpressed by many tumors[94].”
BackgroundCancer immunotherapy: The past, the present and the future
Parish, C. R. (2003) · Immunology & Cell Biology · doi:10.1046/j.0818-9641.2003.01151.x · Cited by 239
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs, R. W., & Carlsten, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4506 · Cited by 236
Gorer, P. A., Lyman, S., & Snell, G. D. (1948) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1948.0026 · Cited by 226
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Wang, R.-F., & Wang, H. Y. (2017) · Cell Research · doi:10.1038/cr.2016.155 · Cited by 225
Haabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembic, Z., Corthay, A., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00174 · Cited by 202
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 199
Immunotherapy for bladder cancer
Green, J., Fuge, O., Allchorne, P., & Vasdev, N. (2015) · Research and Reports in Urology · doi:10.2147/rru.s63447 · Cited by 194
Kučerová, P., & Červinková, M. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000337 · Cited by 178
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Passardi, A., Canale, M., Valgiusti, M., & Ulivi, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061324 · Cited by 172
Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148 · cited 1×
“The cancer cells which are not eliminated and which escape may do this by expressing fewer antigens on their surfaces or even by losing their MHC class I expression[34].”
BackgroundTsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 145
Going viral: a review of replication-selective oncolytic adenoviruses
Larson, C., Oronsky, B. T., Scicinski, J. J., Fanger, G. R., Stirn, M., Oronsky, A. L., & Reid, T. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5116 · Cited by 140
Immunotherapy in Bladder Cancer
Vasekar, M. K., DeGraff, D. J., & Joshi, M. (2016) · Current Molecular Pharmacology · doi:10.2174/1874467208666150716120945 · Cited by 136
Gardner, T. A., Elzey, B. D., & Hahn, N. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19795 · Cited by 133
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 126
Tonegawa, S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.1.203 · Cited by 120
Mino-Kenudson, M. A., & Mino-Kenudson, M. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0009 · Cited by 93
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
Choi, A. H., O’Leary, M., Fong, Y., & Chen, N. G. (2016) · Biomedicines · doi:10.3390/biomedicines4030018 · Cited by 91
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Galbraith, G. M. P. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70546-x · Cited by 72
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
THIERS, B. H. (2006) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70054-6 · Cited by 69
Bacteria as tumor therapeutics?
Oelschlaeger, T. A. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.2.11248 · Cited by 67
Halpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 57
Immune Checkpoint Therapy and the Search for Predictive Biomarkers
Sharma, P. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000185 · Cited by 44
Derosa, L., Routy, B., Enot, D. P., Baciarello, G., Massard, C., Loriot, Y., Fizazi, K. S., Escudier, B. J., Zitvogel, L., & Albiges, L. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.462 · Cited by 39
Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors
Xin, G., Schauder, D., Jing, W., Jiang, A., Joshi, N. S., Johnson, B. D., & Cui, W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614315114 · Cited by 36
Wargo, J. A., Gopalakrishnan, V., Spencer, C. N., Karpinets, T. V., Reuben, A., Andrews, M. C., Tetzlaff, M. T., Lazar, A. J., Hwu, P., Hwu, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3008 · Cited by 34
Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor
Administration, U. S. F. &. D. (2016) · Case Medical Research · doi:10.31525/fda1-ucm526430.htm · Cited by 27
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Patel, S. H., Rimner, A., & Cohen, R. B. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.04 · Cited by 21
Vaccines and Vaccine Adjuvants as Biological Response Modifiers
Speil, C. A., & Rzepka, R. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2011.07.004 · Cited by 12
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
Cancer and the Immune System: The History and Background of Immunotherapy
Abbott, M., & Ustoyev, Y. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.002 · Cited by 489
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L., Azzouqa, A.-G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 340
Metadata
- Authors
- Oiseth, S. J., & Aziz, M. S.
- Venue
- Journal of Cancer Metastasis and Treatment
- Publisher
- OAE Publishing Inc.
- Published
- 2017-10-31
- Volume
- 3
- Issue
- 10
- Pages
- 250
- ISSN
- 2394-4722 (ISSN-L)
- 2454-2857
- OpenAlex
- W2765238085
- Cited by
- 369
- References
- 98
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.